{
  "id": 11197584,
  "title": "Alpha Cognition Announces CONVERGE Real-World Evidence on ZUNVEYL®(Benzgalantamine) Use in Long-Term Care",
  "url": "https://urgent.news/2026/10/01/alpha-cognition-announces-converge-real-world-evidence-on-zunveyl",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-01T12:48:32.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/pmn/business-wire-news-releases-pmn/alpha-cognition-announces-converge-real-world-evidence-on-zunveylbenzgalantamine-use-in-long-term-care"
  },
  "original_language": "en",
  "account": "VANCOUVER, British Columbia and GRAPEVINE, Texas - Alpha Cognition Inc., a pharmaceutical company listed on NASDAQ as ACOG, has unveiled preliminary findings from the CONVERGE study. This study, an ongoing investigation into real-world evidence using extensive long-term care data, concentrated on the titration process and medication combinations for residents receiving ZUNVEYL, a benzgalantamine-based drug, alongside other acetylcholinesterase inhibitors like donepezil, galantamine, and rivastigmine. The primary goal of the CONVERGE program is to generate evidence on how these treatments are utilized in actual long-term care environments, with a focus on determining if patients achieve optimal dosing levels and how their overall medication regimens evolve over time.\n\nThe analysis encompassed a diverse group of long-term care residents, including those who had never been prescribed an acetylcholinesterase inhibitor (AChEI) before, as well as individuals who were switching from another AChEI treatment.",
  "summary": "VANCOUVER, British Columbia & GRAPEVINE, Texas — Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition,” “ACI,” or the “Company”) today announced initial results from CONVERGE, an ongoing retrospective real-world evidence evaluation using longitudinal long-term care medication-administration data. As part of the ongoing CONVERGE evidence-generation program, this analysis focused on 180-day…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}